AmerisourceBergen (NYSE:ABC) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $89.00 price target on the stock. According to Zacks, “AmerisourceBergen continues to gain from its Pharmaceutical segment, World Courier and Specialty Distribution businesses, which have been raking in huge profits over a considerable period of time. Additionally, the company’s Global Commercialization Services and Animal Health unit have been strong. A raised EPS guidance for 2019 instills investors’ optimism in the stock. However, sluggishness at PharMEDium and Lash units have been a headwind over the last couple of quarters. Contraction in gross and operating margin in recent times remains a concern. The company faces other headwinds like conversion of branded drugs and lower price generics. Cutthroat competition in the MedTech space adds to woes. AmerisourceBergen has underperformed the industry year to date.”
Crest Nicholson (LON:CRST) had its target price boosted by Canaccord Genuity from GBX 365 ($4.77) to GBX 370 ($4.83). The firm currently has a hold rating on the stock.
Darden Restaurants (NYSE:DRI) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. They currently have $125.00 target price on the stock. According to Zacks, “Shares of Darden have outperformed the industry in a year. Darden’s earnings met/surpassed the Zacks Consensus Estimate for 18 straight quarters. Estimates for current quarter and year have increased over the past 60 days. Backed by its various sales initiatives and technology-driven moves, the top line is likely to improve in the months ahead. The company’s efforts to check costs are commendable. In fiscal 2018, management realized roughly $10 million of cost synergies and expects to realize the same in the range of $22-$27 million by the end of fiscal 2019. Further, the Cheddar's buyout has added value to Darden's portfolio of differentiated brands. Current-year earnings estimates have also moved north over the past month. However, fierce competition and softer-than-expected consumer demand might keep comps under pressure. Also, rising labor costs and a non-franchised business model may dampen profits.”
Echo Energy (LON:ECHO) had its house stock rating reissued by analysts at Shore Capital.
Eckoh (LON:ECK) had its price target raised by Canaccord Genuity from GBX 50 ($0.65) to GBX 52 ($0.68). The firm currently has a buy rating on the stock.
Edwards Lifesciences (NYSE:EW) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $189.00 price target on the stock. According to Zacks, “Edwards Lifesciences has been seeing strong transcatheter valve sales in the domestic and overseas markets. In the first quarter, it registered strong sales within Critical Care division, boosted by a surge in HemoSphere sales. Currently, Edwards Lifesciences awaits the full-market launch of the HemoSphere platform with FloTrac System and Acumen Hypotension Predictive Index. It is upbeat about the CASMED acquisition, expected to strengthen its position in smart monitoring technologies within the critical care platform. Further, we are pleased with Edwards Lifesciences’ receipt of the CE Mark for PASCAL. Overall, in the past three months, Edwards outperformed its industry. Meanwhile, persistent supply constraints dented Cardioband system sales. This apart, tough competition in the cardiac devices market and reimbursement issue pose concerns.”
Gentex (NASDAQ:GNTX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $25.00 target price on the stock. According to Zacks, “In first-quarter 2019, Gentex’s earnings and revenues surpassed the Zacks Consensus Estimate. Revenues also improved year over year in the quarter. The company aims to attain long-term growth, driven by robust product launches, better mix and unique technology platforms. It remains steadfast in its efforts to provide unique, value-added solutions for its customers. The company pursues an aggressive capital-deployment strategy. Also, rising demand for its dimmable devices is adding to its growth momentum. Moreover, the company is focused on developing dimmable devices that are enabled with new technologies to cater to the increasing demand for technically-advanced auto parts. However, high operating expenses and pricing pressure from automotive customers and competitors are concerns for Gentex.”
ITT (NYSE:ITT) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $65.00 target price on the stock. According to Zacks, “Over the past year, ITT's stock has outperformed the industry. The company expects that strength in the chemical, mining, commercial aerospace and defense businesses, and higher demand for connectors and growth in automotive friction orders will drive revenues in the quarters ahead. Also, operational execution, fall in functional corporate costs, increased productivity and stronger sales volume are expected to boost the company's near-term profitability. In addition, the company intends to become more competent on the back of innovation investments. However, an increase in cost of sales mainly due to tariffs can hurt its margins. Also, given the company's extensive geographic presence, its financial performance is subject to various risks like foreign currency exchange rate fluctuations, interest rates and hyperinflation in foreign countries.”
NCR (NYSE:NCR) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. Zacks Investment Research currently has $34.00 target price on the stock. According to Zacks, “NCR’s first-quarter 2019 results were hurt by foreign exchange headwinds, as significant revenues are generated from outside the United States. The company is affected by a highly leveraged balance sheet and intense competition. Growing competition from companies like Diebold in ATM manufacturing, and Fidelity in financial services is a major concern. However, significant benefits from JetPay acquisition are boosting the top line. NCR continues to focus on cost saving initiatives, which are expected to result in considerable savings in 2019. Moreover, with a diverse self-service portfolio and associated benefits (cost and time savings), we believe that it is poised for solid growth. Shares have outperformed the industry year to date.”
Non-Standard Finance (LON:NSF) had its house stock rating reaffirmed by analysts at Shore Capital.
Provident Financial (LON:PFG) was downgraded by analysts at Canaccord Genuity to a sell rating. Canaccord Genuity currently has GBX 430 ($5.62) price target on the stock, down from their previous price target of GBX 595 ($7.77).
SCHRODERS/PAR VTG FPD 1 (OTCMKTS:SHNWF) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Schroders plc is an asset management company. It manages on behalf of institutional, retail investors, financial institutions and high net worth clients. The company operates primarily in Europe, Asia, the Americas, the Middle East and Africa. Schroders plc is headquartered in London, United Kingdom. “
Sirius Minerals (LON:SXX) had its house stock rating reiterated by analysts at Shore Capital.
Receive News & Ratings for AmerisourceBergen Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen Corp and related companies with MarketBeat.com's FREE daily email newsletter.